Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Insys Therapeutics (INSY) Share Price
Media coverage about Insys Therapeutics (NASDAQ:INSY) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.6080825293915 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- See which Valley public companies were among U.S. stocks that suffered the most last week (finance.yahoo.com)
- Analysts Anticipate Insys Therapeutics Inc (INSY) to Post -$0.11 Earnings Per Share (americanbankingnews.com)
- Insys Therapeutics (INSY) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- New York accuses Insys of deceptively marketing opioid – Reuters – Reuters (reuters.com)
- Insys Therapeutics (INSY) Releases Statement Addressing New York Attorney General’s Complaint – StreetInsider.com (streetinsider.com)
A number of research firms have recently weighed in on INSY. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Tuesday, October 24th. Royal Bank of Canada set a $8.00 price target on shares of Insys Therapeutics and gave the company a “buy” rating in a research note on Friday, October 27th. ValuEngine upgraded shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, November 12th. Finally, Jefferies Group reduced their price target on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $9.38.
WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-insys-therapeutics-insy-share-price.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.